These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36550348)

  • 21. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention.
    Ray KK; Gunn LH; Conde LG; Raal FJ; Wright RS; Gosselin NH; Leiter LA; Koenig W; Schwartz GG; Landmesser U;
    Atherosclerosis; 2024 Apr; 391():117472. PubMed ID: 38447434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.
    Wright RS; Raal FJ; Koenig W; Landmesser U; Leiter LA; Vikarunnessa S; Lesogor A; Maheux P; Talloczy Z; Zang X; Schwartz GG; Ray KK
    Cardiovasc Res; 2024 Oct; 120(12):1400-1410. PubMed ID: 38753448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.
    Wright RS; Koenig W; Landmesser U; Leiter LA; Raal FJ; Schwartz GG; Lesogor A; Maheux P; Stratz C; Zang X; Ray KK
    J Am Coll Cardiol; 2023 Dec; 82(24):2251-2261. PubMed ID: 38057066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
    Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK
    Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
    Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inclisiran - a new era in lipid-lowering therapy].
    Voevoda MI; Gurevich VS; Ezhov MV; Sergienko IV
    Kardiologiia; 2022 Jun; 62(6):57-62. PubMed ID: 35834343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease.
    Koren MJ; Rodriguez F; East C; Toth PP; Watwe V; Abbas CA; Sarwat S; Kleeman K; Kumar B; Ali Y; Jaffrani N
    J Am Coll Cardiol; 2024 May; 83(20):1939-1952. PubMed ID: 38593947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on inclisiran for the treatment of elevated LDL cholesterol.
    Barkas F; Ray K
    Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
    Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
    Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program.
    Stoekenbroek RM; Kallend D; Wijngaard PL; Kastelein JJ
    Future Cardiol; 2018 Nov; 14(6):433-442. PubMed ID: 30375244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
    Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
    Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran.
    Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR
    J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
    Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
    J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary.
    Vohra LI; Rizwan K; Saeed E; Hamza MSA; Ochani S
    Egypt Heart J; 2023 Jul; 75(1):60. PubMed ID: 37439881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials.
    Luo M; Liu Y; Xu X; Liu K; Shen C; Hu H; He Z; Wu F
    Front Pharmacol; 2023; 14():1158274. PubMed ID: 37383716
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.